On October 13, Alignment Healthcare, Inc. rose 8.61% in regular trading, trading at 8.195 USD/share, with Turnover of 35.81 million USD.

The move followed UBS's decision to slash its price target to $9 from $22 while maintaining a Neutral rating, which still implied roughly 10% upside from the prior close and acted as a short-term rebound catalyst. The stock had recently slid to a more than two-year low after the company said its California HMO plan, covering roughly 75% of health plan membership, is expected to receive a 3.5-star federal rating for 2027, down from 4.0 stars in 2026. The decline was primarily attributed to higher industry thresholds and weaker results on certain triple-weighted health outcomes and Part D measures. Alignment said it plans to appeal certain calculations used by the Centers for Medicare & Medicaid Services and pursue litigation challenges. Separately, William Blair downgraded the stock to Market Perform from Outperform.

Alignment Healthcare, Inc., a tech-enabled Medicare advantage company, operates a consumer-centric health care platform. It provides customized health care in the United States to seniors and those who need it through its Medicare advantage plans. The company owns Medicare advantage plans in California, North Carolina, Nevada, Arizona, Florida, and Texas. It was founded in 2013 and is based in Orange, California.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)